Passion for Innovation. Compassion for Patients.™

Daiichi Sankyo Europe GmbH

European News

Edoxaban demonstrates superior efficacy in preventing VTE after total HIP replacement

Daiichi Sankyo completes enrollment of the Edoxaban global phase III engage AF-TIMI 48 study

Daiichi Sankyo raised its profit forecast by almost 18%

AstraZeneca and Daiichi Sankyo announce Co-promotion agreement for Esomeprazole (Nexium)

ArQule and Daiichi Sankyo expand drug discovery collaboration in oncology

Daiichi Sankyo remains on growth course in Europe

Daiichi Sankyo submits first new drug application for oral factor Xa inhibitor edoxaban

Daiichi Sankyo launches guide on International Women's Day

HOKUSAI VTE - largest single phase III trial for the treatment and prevention of recurrent VTE start

Improvement through Movement - new educational programme launched